2026/03/19 by Michel Gagner, Lamees Almutlaq, Rui José Silva Ribeiro +8
Medicine · #Bariatric Surgery and Outcomes #Esophageal and GI Pathology #Gastric Cancer Management and Outcomes
paper · doi:10.1097/xcs.0000000000001926
openalex publication_date 2026/03/19 · openalex created_date 2026/03/20 · openalex updated_date 2026/07/27
BACKGROUND: Minimally invasive magnetic compression technique may simplify the completion of an anastomosis and reduce major surgical complications by obviating permanent staple and suture fixation and enterotomy closures. STUDY DESIGN: A multisite study of magnetic gastroileostomy bipartition (MagGI procedure) as a revisional option for suboptimal sleeve gastrectomy (SG) was conducted in adults (BMI [kg/m 2 ] greater than or equal to 30.0-less than or equal to 50.0). After 1 magnet was delivered endoscopically to the ileum and another to the gastric antrum, the magnets were laparoscopically approximated to initiate gradual compression anastomosis. The 90-day primary feasibility endpoint was magnet placement (≥90% of cases), magnet passage without reintervention, and patent anastomosis creation. Secondary endpoints were weight reduction and improved metabolic indicators. RESULTS: Between November 6, 2023, and July 10, 2024, 20 enrolled patients (mean age 46.1 years, BMI 37.1 ± 0.8, weight 101.0 ± 3.0 kg) underwent SG-revisional MagGI. Primary feasibility endpoint was met: 100.0% magnet placement, median passage 31.0 days; patent anastomosis confirmed (20 of 20). 80.0% (47 of 59) of AEs were low grade (Clavien-Dindo grade I and II). Two intestinal tears (grade III) due to bowel forceps were repaired and resolved; 4 grade-IV SAEs, none related to the magnet device. No anastomotic leak or bleeding; no mortality. Respective 6-month (n = 17) and 12-month (n = 7) weight loss: total 16.9%, 23.4%; excess 57.5%, 66.0%; BMI reduction was 6.2 and 9.1 kg/m 2 . Satisfaction questionnaire (6 months): 100.0% would recommend the procedure. CONCLUSIONS: Preliminary findings suggested that SG-revisional MagGI was technically feasible and achieved a promising excess weight loss of 66.0%. Longer-term follow-up in larger cohorts is needed to establish safety and efficacy.